Prevalence of Fatigue and Associated Factors Among Cancer Patients Attending Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia.
Ethiopia
cancer
chemotherapy
fatigue
specialized hospital
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
11
2020
accepted:
21
01
2021
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
5
3
2021
Statut:
epublish
Résumé
Fatigue is a subjective and distressing symptom in cancer patients and has profound effects on daily life. The rates of fatigue during treatment are reported to be 25-90%. Its causes are secondary to their treatment course, cancer itself and associated factors. To assess the prevalence of fatigue and associated factors among cancer patients at Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia, 2019. A cross-sectional study design was conducted on cancer patients undergoing treatment in Tikur Anbessa Specialized Hospital. A sample of 278 was selected using systematic random sampling technique and Brief Fatigue Inventory questionnaire was used for data collection. The data were entered into EPI data version 3.1 and transferred to SPSS version 24 for analysis. Bivariate and multivariable logistic regression were conducted to summarize the data. The significant statistical test was determined at 95% confidence interval and at p<0.05. The mean age of the participants was 44.9 ± 14 years. The prevalence of fatigue identified by this study was 208 (74.8%). Age, stage of cancer, presence of infection, type of cancer, and type of treatment had shown a significant association with fatigue [AOR = 3.15, 95% CI: (1.35-7.34)], [AOR = 0.02, 95% CI: (0.003-0.172)], [AOR = 4.15, 95% CI: (1.06-16.07)], [AOR = 5.19, 95% CI: (1.59-16.90)], [AOR = 0.18, 95% CI: (0.07-0.462)] respectively. The prevalence of fatigue in cancer patients in this study was high. Risk factors were age of the patients, stage of cancer, presence of infection, cervical cancer and radiation therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Fatigue is a subjective and distressing symptom in cancer patients and has profound effects on daily life. The rates of fatigue during treatment are reported to be 25-90%. Its causes are secondary to their treatment course, cancer itself and associated factors.
PURPOSE
OBJECTIVE
To assess the prevalence of fatigue and associated factors among cancer patients at Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia, 2019.
PATIENTS AND METHODS
METHODS
A cross-sectional study design was conducted on cancer patients undergoing treatment in Tikur Anbessa Specialized Hospital. A sample of 278 was selected using systematic random sampling technique and Brief Fatigue Inventory questionnaire was used for data collection. The data were entered into EPI data version 3.1 and transferred to SPSS version 24 for analysis. Bivariate and multivariable logistic regression were conducted to summarize the data. The significant statistical test was determined at 95% confidence interval and at p<0.05.
RESULTS
RESULTS
The mean age of the participants was 44.9 ± 14 years. The prevalence of fatigue identified by this study was 208 (74.8%). Age, stage of cancer, presence of infection, type of cancer, and type of treatment had shown a significant association with fatigue [AOR = 3.15, 95% CI: (1.35-7.34)], [AOR = 0.02, 95% CI: (0.003-0.172)], [AOR = 4.15, 95% CI: (1.06-16.07)], [AOR = 5.19, 95% CI: (1.59-16.90)], [AOR = 0.18, 95% CI: (0.07-0.462)] respectively.
CONCLUSION
CONCLUSIONS
The prevalence of fatigue in cancer patients in this study was high. Risk factors were age of the patients, stage of cancer, presence of infection, cervical cancer and radiation therapy.
Identifiants
pubmed: 33658853
doi: 10.2147/CMAR.S291298
pii: 291298
pmc: PMC7917325
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1909-1916Informations de copyright
© 2021 Nugusse et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest for this work.
Références
J Pain Symptom Manage. 2010 Aug;40(2):217-23
pubmed: 20541901
Support Care Cancer. 2002 Jul;10(5):389-98
pubmed: 12136222
Lancet. 2003 Aug 23;362(9384):640-50
pubmed: 12944066
J Clin Oncol. 2001 Jul 15;19(14):3385-91
pubmed: 11454886
JMIR Cancer. 2018 Dec 21;4(2):e10932
pubmed: 30578238
Oncologist. 2003;8 Suppl 1:10-4
pubmed: 12626782
Oncologist. 2016 Nov;21(11):1349-1354
pubmed: 27449523
Indian J Palliat Care. 2017 Apr-Jun;23(2):207-211
pubmed: 28503042
Oncologist. 2006 Feb;11(2):184-96
pubmed: 16476839
Ann Oncol. 2011 Jun;22(6):1273-1279
pubmed: 21325448
Am Fam Physician. 2001 Sep 1;64(5):807-14
pubmed: 11563572
Oncologist. 2012;17(4):569-76
pubmed: 22398160
Cardiooncology. 2018 Jun 15;4:5
pubmed: 32154005
Cancer Nurs. 2015 Jan-Feb;38(1):E29-54
pubmed: 24831042
Support Care Cancer. 2018 Oct;26(10):3353-3364
pubmed: 29961146
Curr Pain Headache Rep. 2006 Aug;10(4):260-9
pubmed: 16834940
Clin Colorectal Cancer. 2017 Dec;16(4):275-285
pubmed: 29066018
Med Clin North Am. 2017 Nov;101(6):1085-1097
pubmed: 28992856
Gynecol Oncol. 2015 Mar;136(3):446-52
pubmed: 25458588
Phys Ther. 2004 Aug;84(8):736-43
pubmed: 15283624
J Cancer Res Ther. 2017 Oct-Dec;13(6):916-929
pubmed: 29237952
Cancer. 2003 Nov 1;98(9):1786-801
pubmed: 14584059
Ann Oncol. 2004 May;15(5):712-20
pubmed: 15111337
Clin J Oncol Nurs. 2014;18 Suppl:38-58
pubmed: 25427608
Cancer Invest. 2000;18(1):11-9
pubmed: 10701362
BMC Cancer. 2010 Aug 23;10:453
pubmed: 20731876
Clin Cornerstone. 2004;6 Suppl 1D:S15-21
pubmed: 15675653